2026 Interim report
Filed with HKEX · Stock code 9966 · · 83 pages · English
Summary by 6ix AI
The report includes a comprehensive overview of the company's product pipeline, including innovative therapies and their development stages. It also discusses the company's research and development capabilities and recent achievements in clinical trials and regulatory approvals. Financial highlights and condensed consolidated financial statements are presented to provide insights into the company's financial health.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Alphamab Oncology
- 2026 ASCO Preview | Alphamab Oncology to Present Clinical Data of TROP2/HER3 Bispecific ADC JSKN016 for HER2-Negative Breast Cancer
- 2026 ASCO Preview | Results from Phase III Study of Anbenitamab (KN026) Combined with HB1801 in Neoadjuvant Treatment for Breast Cancer Selected for LBA Oral Presentation
- Alphamab Oncology Announces the Phase III Clinical Study of Anbenitamab (KN026) Combined with HB1801 as Neoadjuvant Treatment for Breast Cancer Has Met the Primary Endpoint
- Alphamab Oncology Reports Full Year 2025 Financial Results and Business Highlights
- Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study of Anbenitamab (KN026) Combined with HB1801 and Chemotherapy as Adjuvant Treatment of Breast Cancer
Later from Alphamab Oncology
- Next Day Disclosure Return
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Discloseable transaction - exercise of warrant to subscribe for preferred stock of pathos AI, inc.
- Voluntary announcement - latest research results of two phase III clinical studies of anbenitamab (KN026) were presented at the 2026 ESMO Congress as lba oral presentations
- Voluntary announcement - results of a phase I/II clinical study of JSKN033 in patients with CC following failure of standard treatment were presented at the 2026 esmo congress as a rapid oral presentation
Follow Alphamab Oncology into a list and get an email when it puts out news.
Follow Alphamab Oncology